{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:06:04Z","timestamp":1790111164465,"version":"4.0.1"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013140","name":"Colorectal Cancer Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013140","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.trecan.2026.08.010","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:12:29Z","timestamp":1789992749000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Not \u2018cold\u2019 but conditional: emerging principles of immunotherapy in colorectal cancer"],"prefix":"10.1016","author":[{"given":"Evan R.","family":"Beiter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8962-3527","authenticated-orcid":false,"given":"Christopher T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2026.08.010_bb0005","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/S0140-6736(25)02025-2","article-title":"Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial","volume":"406","author":"Hecht","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2026.08.010_bb0010","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1200\/JCO.2010.30.5425","article-title":"Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction","volume":"29","author":"Mlecnik","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.08.010_bb0015","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41588-022-01088-x","article-title":"Single-cell analyses define a continuum of cell state and composition changes in the malignant transformation of polyps to colorectal cancer","volume":"54","author":"Becker","year":"2022","journal-title":"Nat. Genet."},{"key":"10.1016\/j.trecan.2026.08.010_bb0020","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.annonc.2024.06.015","article-title":"Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial","volume":"35","author":"Lin","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.08.010_bb0025","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S1470-2045(25)00286-4","volume":"26","author":"Tian","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.08.010_bb0030","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41586-025-09679-4","article-title":"Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers","volume":"648","author":"Tan","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.08.010_bb0035","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.08.010_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e13048","article-title":"Heterogeneity of PD-L1 expression and CD8 lymphocyte infiltration in metastatic colorectal cancer and their prognostic significance","volume":"9","author":"Xin","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.trecan.2026.08.010_bb0045","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41591-024-03083-7","article-title":"Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","volume":"30","author":"Bullock","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.08.010_bb0050","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO-25-01044","article-title":"Immunotherapy efficacy in mismatch repair-proficient colorectal cancer patients with and without liver metastases","volume":"44","author":"Beiter","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.08.010_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104135","article-title":"Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study","volume":"10","author":"Antoniotti","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.trecan.2026.08.010_bb0060","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1016\/j.cell.2021.08.003","article-title":"Spatially organized multicellular immune hubs in human colorectal cancer","volume":"184","author":"Pelka","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2026.08.010_bb0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54710-3","article-title":"Spatially organized tumor-stroma boundary determines the efficacy of immunotherapy in colorectal cancer patients","volume":"15","author":"Feng","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.08.010_bb0070","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1200\/JCO.23.02728","article-title":"Upfront fluorouracil, leucovorin, oxaliplatin, and irinotecan plus bevacizumab with or without atezolizumab for patients with metastatic colorectal cancer: updated and overall survival results of the ATEZOTRIBE study","volume":"42","author":"Antoniotti","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.08.010_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.111722","article-title":"Design of a fragment crystallizable-engineered tetravalent bispecific antibody targeting programmed cell death-1 and vascular endothelial growth factor with cooperative biological effects","volume":"28","author":"Zhong","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.trecan.2026.08.010_bb0080","doi-asserted-by":"crossref","first-page":"S913","DOI":"10.1016\/j.annonc.2025.08.2153","article-title":"1522MO A phase I study of INCA33890, a PD-1\/TGF\u03b2R2 bispecific antibody, for advanced solid tumours","volume":"36","author":"Garralda","year":"2025","journal-title":"Ann. Oncol."}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326002062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326002062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:11:30Z","timestamp":1790107890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803326002062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":16,"alternative-id":["S2405803326002062"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2026.08.010","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Not \u2018cold\u2019 but conditional: emerging principles of immunotherapy in colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2026.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}